Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease

Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies. Approach and Results We conducted a territory‐wide...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 76; no. 5; pp. 1409 - 1422
Main Authors Zhang, Xinrong, Wong, Grace Lai‐Hung, Yip, Terry Cheuk‐Fung, Cheung, Johnny T. K., Tse, Yee‐Kit, Hui, Vicki Wing‐Ki, Lin, Huapeng, Lai, Jimmy Che‐To, Chan, Henry Lik‐Yuen, Kong, Alice Pik‐Shan, Wong, Vincent Wai‐Sun
Format Journal Article
LanguageEnglish
Published Hoboken Wolters Kluwer Health, Inc 01.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies. Approach and Results We conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results. Conclusions Age rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age. Diabetes is an important risk factor for nonalcoholic fatty liver disease (NAFLD) and its severity. However, it is difficult to screen every diabetic patient for NAFLD because of the large number of patients. In a study of 7028 patients with NAFLD and type 2 diabetes from Hong Kong, we showed that the vast majority of patients developed liver‐related complications after the age of 50 years. In contrast, liver‐related events increased linearly with the duration of diabetes with no threshold effect. Our study suggests that screening for liver disease should be based on age instead of the duration of diabetes.
AbstractList Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver-related event development to guide screening strategies.BACKGROUND AND AIMSSeveral guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver-related event development to guide screening strategies.We conducted a territory-wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow-up. The primary endpoint was liver-related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow-up of 77,308 person-years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver-related events at the age of <40, 40-50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40-50, and ≥50 years, respectively. In contrast, liver-related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver-related events. Substitution of cirrhosis with the aspartate aminotransferase-to-platelet ratio index or the Fibrosis-4 index yielded similar results.APPROACH AND RESULTSWe conducted a territory-wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow-up. The primary endpoint was liver-related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow-up of 77,308 person-years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver-related events at the age of <40, 40-50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40-50, and ≥50 years, respectively. In contrast, liver-related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver-related events. Substitution of cirrhosis with the aspartate aminotransferase-to-platelet ratio index or the Fibrosis-4 index yielded similar results.Age rather than duration of T2D predicts liver-related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.CONCLUSIONSAge rather than duration of T2D predicts liver-related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.
Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies. Approach and Results We conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results. Conclusions Age rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age. Diabetes is an important risk factor for nonalcoholic fatty liver disease (NAFLD) and its severity. However, it is difficult to screen every diabetic patient for NAFLD because of the large number of patients. In a study of 7028 patients with NAFLD and type 2 diabetes from Hong Kong, we showed that the vast majority of patients developed liver‐related complications after the age of 50 years. In contrast, liver‐related events increased linearly with the duration of diabetes with no threshold effect. Our study suggests that screening for liver disease should be based on age instead of the duration of diabetes.
Background and AimsSeveral guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies.Approach and ResultsWe conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results.ConclusionsAge rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.
Author Yip, Terry Cheuk‐Fung
Zhang, Xinrong
Wong, Vincent Wai‐Sun
Lai, Jimmy Che‐To
Tse, Yee‐Kit
Chan, Henry Lik‐Yuen
Hui, Vicki Wing‐Ki
Kong, Alice Pik‐Shan
Lin, Huapeng
Cheung, Johnny T. K.
Wong, Grace Lai‐Hung
Author_xml – sequence: 1
  givenname: Xinrong
  orcidid: 0000-0002-8393-8904
  surname: Zhang
  fullname: Zhang, Xinrong
  organization: The Chinese University of Hong Kong
– sequence: 2
  givenname: Grace Lai‐Hung
  orcidid: 0000-0002-2863-9389
  surname: Wong
  fullname: Wong, Grace Lai‐Hung
  organization: The Chinese University of Hong Kong
– sequence: 3
  givenname: Terry Cheuk‐Fung
  surname: Yip
  fullname: Yip, Terry Cheuk‐Fung
  organization: The Chinese University of Hong Kong
– sequence: 4
  givenname: Johnny T. K.
  orcidid: 0000-0001-7455-5218
  surname: Cheung
  fullname: Cheung, Johnny T. K.
  organization: The Chinese University of Hong Kong
– sequence: 5
  givenname: Yee‐Kit
  surname: Tse
  fullname: Tse, Yee‐Kit
  organization: The Chinese University of Hong Kong
– sequence: 6
  givenname: Vicki Wing‐Ki
  surname: Hui
  fullname: Hui, Vicki Wing‐Ki
  organization: The Chinese University of Hong Kong
– sequence: 7
  givenname: Huapeng
  surname: Lin
  fullname: Lin, Huapeng
  organization: The Chinese University of Hong Kong
– sequence: 8
  givenname: Jimmy Che‐To
  surname: Lai
  fullname: Lai, Jimmy Che‐To
  organization: The Chinese University of Hong Kong
– sequence: 9
  givenname: Henry Lik‐Yuen
  surname: Chan
  fullname: Chan, Henry Lik‐Yuen
  organization: Union Hospital
– sequence: 10
  givenname: Alice Pik‐Shan
  surname: Kong
  fullname: Kong, Alice Pik‐Shan
  organization: The Chinese University of Hong Kong
– sequence: 11
  givenname: Vincent Wai‐Sun
  orcidid: 0000-0003-2215-9410
  surname: Wong
  fullname: Wong, Vincent Wai‐Sun
  email: wongv@cuhk.edu.hk
  organization: The Chinese University of Hong Kong
BookMark eNp10UtKBDEQBuAgCo6PhTcIuNFFayX9Si9FfIGgiK6bpLviRGNnTDIO48ojeEZPYpwRBNFVsvj-Sqpqg6wObkBCdhgcMAB-OMbJQc6LulohI1byOsvzElbJCHgNWcPyZp1shPAAAE3BxYi83pjwSJ2m1ryg_3h792hlxJ7iCw4xUDWn8h6pHHraG6kwYqD91Mto3EDNQCfptoAzE8c_5Munn0nbubGzpqNaxjhfPpJUQBlwi6xpaQNuf5-b5O705Pb4PLu8Ors4PrrMurwSVSYKwVilGBMAVaMUKF73kislgGtd6B5KrVKXumGCLyJMoBJlx-saCuT5Jtlb1p149zzFENsnEzq0Vg7opqHlVVEAB17mie7-og9u6lMbSdW8bETDiyqpw6XqvAvBo247ExcTiV4a2zJov3bRpl20i12kxP6vxMSbJ-nnf9rv6jNjcf4_bM9PrpeJT2aOm-E
CitedBy_id crossref_primary_10_1111_liv_15718
crossref_primary_10_1097_HEP_0000000000000432
crossref_primary_10_1053_j_gastro_2023_06_008
crossref_primary_10_3390_biomedicines11041097
crossref_primary_10_1016_j_jceh_2025_102536
crossref_primary_10_15212_CVIA_2023_0073
crossref_primary_10_1111_liv_15880
crossref_primary_10_1002_ueg2_12514
crossref_primary_10_1002_poh2_31
crossref_primary_10_1097_HC9_0000000000000148
crossref_primary_10_1038_s41598_024_64928_2
crossref_primary_10_1053_j_gastro_2023_01_040
crossref_primary_10_7759_cureus_49286
crossref_primary_10_1002_mco2_781
crossref_primary_10_1111_hepr_14133
crossref_primary_10_1016_j_jhepr_2023_100791
crossref_primary_10_1159_000541945
crossref_primary_10_55544_jrasb_2_6_15
crossref_primary_10_1136_gutjnl_2023_330269
crossref_primary_10_3389_fendo_2023_1199429
crossref_primary_10_3390_jpm14010061
crossref_primary_10_3390_ijms26010050
crossref_primary_10_1016_j_jhep_2023_04_036
crossref_primary_10_1111_liv_16120
crossref_primary_10_1136_bmjopen_2023_080549
crossref_primary_10_1007_s10620_024_08723_z
crossref_primary_10_1038_s41572_025_00599_1
crossref_primary_10_1002_ueg2_12508
crossref_primary_10_1016_j_mcna_2022_12_003
crossref_primary_10_3390_biomedicines11092416
crossref_primary_10_47102_annals_acadmedsg_2022284
crossref_primary_10_1016_j_heliyon_2024_e37869
crossref_primary_10_31146_1682_8658_ecg_223_3_25_32
crossref_primary_10_3350_cmh_2023_0066
crossref_primary_10_1097_HEP_0000000000000812
Cites_doi 10.1056/NEJMoa1912035
10.1002/hep.28431
10.1007/s00125-021-05585-2
10.1111/liv.14638
10.1111/jvh.13307
10.1016/j.ejim.2020.08.005
10.1038/s41575-018-0014-9
10.1111/j.1478-3231.2011.02482.x
10.1016/j.jhep.2020.06.007
10.1002/hep.31142
10.1016/j.cgh.2014.04.014
10.1016/j.cgh.2017.02.031
10.1007/s00535-020-01754-z
10.1002/hep.30858
10.1136/gutjnl-2015-309265
10.1016/j.jhep.2015.11.004
10.1016/j.jhep.2019.03.033
10.1002/cncr.24982
10.1111/apt.14172
10.1002/sim.7501
10.1002/hep4.1705
10.1007/s00535-010-0310-9
10.1053/j.gastro.2018.04.034
10.1136/gutjnl-2011-300342
10.1002/hep.31726
10.1002/hep.29367
10.1002/hep.29660
ContentType Journal Article
Copyright 2022 American Association for the Study of Liver Diseases.
Copyright_xml – notice: 2022 American Association for the Study of Liver Diseases.
DBID AAYXX
CITATION
7T5
7TM
7TO
7U9
H94
K9.
7X8
DOI 10.1002/hep.32476
DatabaseName CrossRef
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1527-3350
EndPage 1422
ExternalDocumentID 10_1002_hep_32476
HEP32476
Genre article
GrantInformation_xml – fundername: The Chinese University of Hong Kong
  funderid: 2020.045
GroupedDBID ---
--K
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
186
1B1
1CY
1L6
1OB
1OC
1ZS
1~5
24P
31~
33P
3O-
3SF
3WU
4.4
4G.
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AALRI
AANHP
AAONW
AAQFI
AAQQT
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABLJU
ABMAC
ABOCM
ABPVW
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACLDA
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AECAP
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFFNX
AFGKR
AFPWT
AFUWQ
AFZJQ
AHMBA
AIACR
AIURR
AIWBW
AJAOE
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
F00
F01
F04
F5P
FD8
FDB
FEDTE
FGOYB
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IHE
IX1
J0M
J5H
JPC
KBYEO
KQQ
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
M65
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NQ-
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
R2-
RGB
RIG
RIWAO
RJQFR
ROL
RPZ
RWI
RX1
RYL
SEW
SSZ
SUPJJ
TEORI
UB1
V2E
V9Y
W2D
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
X7M
XG1
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ABJNI
ACZKN
AFNMH
AGQPQ
AHQVU
CITATION
MEWTI
WXSBR
7T5
7TM
7TO
7U9
AAMMB
ADSXY
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
7X8
ID FETCH-LOGICAL-c3686-848116b1180069bb0b27da2bb802ff4fd05fb335f9182c368618eb85c27704e23
IEDL.DBID DR2
ISSN 0270-9139
1527-3350
IngestDate Thu Jul 10 22:31:56 EDT 2025
Wed Aug 13 05:02:15 EDT 2025
Tue Jul 01 03:34:03 EDT 2025
Thu Apr 24 23:09:10 EDT 2025
Wed Jan 22 16:23:51 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3686-848116b1180069bb0b27da2bb802ff4fd05fb335f9182c368618eb85c27704e23
Notes Funding information
This study was supported in part by a direct grant from The Chinese University of Hong Kong (2020.045)
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7455-5218
0000-0003-2215-9410
0000-0002-8393-8904
0000-0002-2863-9389
PQID 2725989246
PQPubID 996352
PageCount 14
ParticipantIDs proquest_miscellaneous_2644020253
proquest_journals_2725989246
crossref_citationtrail_10_1002_hep_32476
crossref_primary_10_1002_hep_32476
wiley_primary_10_1002_hep_32476_HEP32476
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2022
2022-11-00
20221101
PublicationDateYYYYMMDD 2022-11-01
PublicationDate_xml – month: 11
  year: 2022
  text: November 2022
PublicationDecade 2020
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
PublicationTitle Hepatology (Baltimore, Md.)
PublicationYear 2022
Publisher Wolters Kluwer Health, Inc
Publisher_xml – name: Wolters Kluwer Health, Inc
References 2015; 13
2012; 61
2017; 7
2021; 5
2019; 71
2020; 382
2020; 40
2020; 82
2017; 46
2011; 31
2022; 65
2018; 67
2021; 74
2010; 45
2018; 155
2017; 96
2021; 12
2021; 56
2017; 15
2017; 36
2010; 116
2021
2020; 73
2020; 72
2020; 71
2016; 65
2015; 2015
2016; 64
2020; 27
2018; 15
(hep32476-bib-0006-20241017) 2018; 67
(hep32476-bib-0009-20241017) 2010; 116
(hep32476-bib-0014-20241017) 2021; 5
(hep32476-bib-0025-20241017) 2020; 382
(hep32476-bib-0023-20241017) 2020; 73
(hep32476-bib-0026-20241017) 2021; 12
(hep32476-bib-0011-20241017) 2021
(hep32476-bib-0029-20241017) 2010; 45
(hep32476-bib-0004-20241017) 2020; 72
(hep32476-bib-0013-20241017) 2018; 15
(hep32476-bib-0019-20241017) 2017; 96
(hep32476-bib-0008-20241017) 2015; 2015
(hep32476-bib-0015-20241017) 2017; 36
(hep32476-bib-0033-20241017) 2012; 61
(hep32476-bib-0003-20241017) 2016; 65
(hep32476-bib-0016-20241017) 2011; 31
(hep32476-bib-0028-20241017) 2020; 27
(hep32476-bib-0024-20241017) 2019; 71
(hep32476-bib-0021-20241017) 2020; 82
(hep32476-bib-0001-20241017) 2016; 64
(hep32476-bib-0020-20241017) 2015; 13
(hep32476-bib-0031-20241017) 2017; 46
(hep32476-bib-0012-20241017) 2021; 74
(hep32476-bib-0005-20241017) 2016; 64
(hep32476-bib-0030-20241017) 2021; 56
(hep32476-bib-0007-20241017) 2017; 15
(hep32476-bib-0027-20241017) 2017; 7
(hep32476-bib-0010-20241017) 2018; 67
(hep32476-bib-0022-20241017) 2018; 155
(hep32476-bib-0002-20241017) 2020; 40
(hep32476-bib-0018-20241017) 2022; 65
(hep32476-bib-0032-20241017) 2021; 74
(hep32476-bib-0017-20241017) 2020; 71
References_xml – volume: 36
  start-page: 4391
  issue: 27
  year: 2017
  end-page: 400
  article-title: Practical recommendations for reporting Fine‐Gray model analyses for competing risk data
  publication-title: Stat Med
– volume: 65
  start-page: 1359
  issue: 8
  year: 2016
  end-page: 68
  article-title: Screening diabetic patients for non‐alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
  publication-title: Gut
– volume: 5
  start-page: 1212
  issue: 7
  year: 2021
  end-page: 23
  article-title: Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory‐wide cohort study
  publication-title: Hepatol Commun
– volume: 56
  start-page: 261
  issue: 3
  year: 2021
  end-page: 73
  article-title: Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan
  publication-title: J Gastroenterol
– volume: 96
  issue: 13
  year: 2017
  article-title: Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis C patients in China
  publication-title: Medicine
– volume: 65
  start-page: 3
  issue: 1
  year: 2022
  end-page: 13
  article-title: Interpreting global trends in type 2 diabetes complications and mortality
  publication-title: Diabetologia
– volume: 15
  start-page: 1453
  issue: 9
  year: 2017
  end-page: 60.e1
  article-title: Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis
  publication-title: Clin Gastroenterol Hepatol
– volume: 73
  start-page: 1023
  issue: 5
  year: 2020
  end-page: 9
  article-title: Repeated FIB‐4 measurements can help identify individuals at risk of severe liver disease
  publication-title: J Hepatol
– volume: 12
  issue: 3
  year: 2021
  article-title: Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog
  publication-title: Clin Transl Gastroenterol
– year: 2021
  article-title: Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 31
  start-page: 700
  issue: 5
  year: 2011
  end-page: 6
  article-title: Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors
  publication-title: Liver Int
– volume: 71
  start-page: 371
  issue: 2
  year: 2019
  end-page: 78
  article-title: Prospective evaluation of a primary care referral pathway for patients with non‐alcoholic fatty liver disease
  publication-title: J Hepatol
– volume: 64
  start-page: 73
  issue: 1
  year: 2016
  end-page: 84
  article-title: Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes
  publication-title: Hepatology
– volume: 382
  start-page: 1018
  issue: 11
  year: 2020
  end-page: 28
  article-title: Association of aspirin with hepatocellular carcinoma and liver‐related mortality
  publication-title: N Engl J Med
– volume: 45
  start-page: 1097
  issue: 11
  year: 2010
  end-page: 102
  article-title: Mechanisms by which thiazolidinediones induce anti‐cancer effects in cancers in digestive organs
  publication-title: J Gastroenterol
– volume: 13
  start-page: 643
  issue: 4
  year: 2015
  end-page: 54.e9
  article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies
  publication-title: Clin Gastroenterol Hepatol
– volume: 67
  start-page: 1797
  issue: 5
  year: 2018
  end-page: 806
  article-title: Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies
  publication-title: Hepatology
– volume: 15
  start-page: 461
  issue: 8
  year: 2018
  end-page: 78
  article-title: Noninvasive biomarkers in NAFLD and NASH ‐ current progress and future promise
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 155
  start-page: 443
  issue: 2
  year: 2018
  end-page: 57.e417
  article-title: Fibrosis severity as a determinant of cause‐specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi‐national cohort study
  publication-title: Gastroenterology
– volume: 71
  start-page: 907
  issue: 3
  year: 2020
  end-page: 16
  article-title: Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 116
  start-page: 1938
  issue: 8
  year: 2010
  end-page: 46
  article-title: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
  publication-title: Cancer
– volume: 74
  start-page: 474
  issue: 1
  year: 2021
  end-page: 82
  article-title: Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement
  publication-title: Hepatology
– volume: 7
  start-page: 1606
  issue: 7
  year: 2017
  end-page: 16
  article-title: The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population‐based cohort study in Taiwan
  publication-title: Am J Cancer Res
– volume: 61
  start-page: 409
  issue: 3
  year: 2012
  end-page: 15
  article-title: Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography
  publication-title: Gut
– volume: 27
  start-page: 904
  issue: 9
  year: 2020
  end-page: 14
  article-title: Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B
  publication-title: J Viral Hepat
– volume: 72
  start-page: 1230
  issue: 4
  year: 2020
  end-page: 241
  article-title: Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study
  publication-title: Hepatology
– volume: 74
  start-page: 928
  issue: S1
  year: 2021
  end-page: 9
  article-title: Accuracy of administrative coding for nonalcoholic fatty liver disease and related hepatic complications: a single‐center validation study
  publication-title: Hepatology
– volume: 46
  start-page: 447
  issue: 4
  year: 2017
  end-page: 56
  article-title: Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population
  publication-title: Aliment Pharmacol Ther
– volume: 40
  start-page: 2719
  issue: 11
  year: 2020
  end-page: 31
  article-title: Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease
  publication-title: Liver Int
– volume: 2015
  year: 2015
  article-title: Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk
  publication-title: Gastroenterol Res Pract
– volume: 67
  start-page: 328
  issue: 1
  year: 2018
  end-page: 57
  article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases
  publication-title: Hepatology
– volume: 64
  start-page: 1388
  issue: 6
  year: 2016
  end-page: 402
  article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease
  publication-title: J Hepatol
– volume: 82
  start-page: 68
  year: 2020
  end-page: 75
  article-title: Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography ‐ a prospective, cross sectional study
  publication-title: Eur J Intern Med
– volume: 382
  start-page: 1018
  issue: 11
  year: 2020
  ident: hep32476-bib-0025-20241017
  article-title: Association of aspirin with hepatocellular carcinoma and liver‐related mortality
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1912035
– volume: 64
  start-page: 73
  issue: 1
  year: 2016
  ident: hep32476-bib-0001-20241017
  article-title: Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes
  publication-title: Hepatology
  doi: 10.1002/hep.28431
– year: 2021
  ident: hep32476-bib-0011-20241017
  article-title: Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 96
  issue: 13
  year: 2017
  ident: hep32476-bib-0019-20241017
  article-title: Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis C patients in China
  publication-title: Medicine
– volume: 65
  start-page: 3
  issue: 1
  year: 2022
  ident: hep32476-bib-0018-20241017
  article-title: Interpreting global trends in type 2 diabetes complications and mortality
  publication-title: Diabetologia
  doi: 10.1007/s00125-021-05585-2
– volume: 40
  start-page: 2719
  issue: 11
  year: 2020
  ident: hep32476-bib-0002-20241017
  article-title: Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease
  publication-title: Liver Int
  doi: 10.1111/liv.14638
– volume: 27
  start-page: 904
  issue: 9
  year: 2020
  ident: hep32476-bib-0028-20241017
  article-title: Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B
  publication-title: J Viral Hepat
  doi: 10.1111/jvh.13307
– volume: 82
  start-page: 68
  year: 2020
  ident: hep32476-bib-0021-20241017
  article-title: Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography ‐ a prospective, cross sectional study
  publication-title: Eur J Intern Med
  doi: 10.1016/j.ejim.2020.08.005
– volume: 15
  start-page: 461
  issue: 8
  year: 2018
  ident: hep32476-bib-0013-20241017
  article-title: Noninvasive biomarkers in NAFLD and NASH ‐ current progress and future promise
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-018-0014-9
– volume: 31
  start-page: 700
  issue: 5
  year: 2011
  ident: hep32476-bib-0016-20241017
  article-title: Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors
  publication-title: Liver Int
  doi: 10.1111/j.1478-3231.2011.02482.x
– volume: 73
  start-page: 1023
  issue: 5
  year: 2020
  ident: hep32476-bib-0023-20241017
  article-title: Repeated FIB‐4 measurements can help identify individuals at risk of severe liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.06.007
– volume: 72
  start-page: 1230
  issue: 4
  year: 2020
  ident: hep32476-bib-0004-20241017
  article-title: Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study
  publication-title: Hepatology
  doi: 10.1002/hep.31142
– volume: 7
  start-page: 1606
  issue: 7
  year: 2017
  ident: hep32476-bib-0027-20241017
  article-title: The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population‐based cohort study in Taiwan
  publication-title: Am J Cancer Res
– volume: 13
  start-page: 643
  issue: 4
  year: 2015
  ident: hep32476-bib-0020-20241017
  article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2014.04.014
– volume: 15
  start-page: 1453
  issue: 9
  year: 2017
  ident: hep32476-bib-0007-20241017
  article-title: Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2017.02.031
– volume: 74
  start-page: 928
  issue: S1
  year: 2021
  ident: hep32476-bib-0012-20241017
  article-title: Accuracy of administrative coding for nonalcoholic fatty liver disease and related hepatic complications: a single‐center validation study
  publication-title: Hepatology
– volume: 56
  start-page: 261
  issue: 3
  year: 2021
  ident: hep32476-bib-0030-20241017
  article-title: Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-020-01754-z
– volume: 71
  start-page: 907
  issue: 3
  year: 2020
  ident: hep32476-bib-0017-20241017
  article-title: Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.30858
– volume: 65
  start-page: 1359
  issue: 8
  year: 2016
  ident: hep32476-bib-0003-20241017
  article-title: Screening diabetic patients for non‐alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
  publication-title: Gut
  doi: 10.1136/gutjnl-2015-309265
– volume: 64
  start-page: 1388
  issue: 6
  year: 2016
  ident: hep32476-bib-0005-20241017
  article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.11.004
– volume: 12
  issue: 3
  year: 2021
  ident: hep32476-bib-0026-20241017
  article-title: Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog
  publication-title: Clin Transl Gastroenterol
– volume: 71
  start-page: 371
  issue: 2
  year: 2019
  ident: hep32476-bib-0024-20241017
  article-title: Prospective evaluation of a primary care referral pathway for patients with non‐alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.03.033
– volume: 116
  start-page: 1938
  issue: 8
  year: 2010
  ident: hep32476-bib-0009-20241017
  article-title: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.24982
– volume: 46
  start-page: 447
  issue: 4
  year: 2017
  ident: hep32476-bib-0031-20241017
  article-title: Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.14172
– volume: 36
  start-page: 4391
  issue: 27
  year: 2017
  ident: hep32476-bib-0015-20241017
  article-title: Practical recommendations for reporting Fine‐Gray model analyses for competing risk data
  publication-title: Stat Med
  doi: 10.1002/sim.7501
– volume: 5
  start-page: 1212
  issue: 7
  year: 2021
  ident: hep32476-bib-0014-20241017
  article-title: Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory‐wide cohort study
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.1705
– volume: 45
  start-page: 1097
  issue: 11
  year: 2010
  ident: hep32476-bib-0029-20241017
  article-title: Mechanisms by which thiazolidinediones induce anti‐cancer effects in cancers in digestive organs
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-010-0310-9
– volume: 155
  start-page: 443
  issue: 2
  year: 2018
  ident: hep32476-bib-0022-20241017
  article-title: Fibrosis severity as a determinant of cause‐specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi‐national cohort study
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.04.034
– volume: 61
  start-page: 409
  issue: 3
  year: 2012
  ident: hep32476-bib-0033-20241017
  article-title: Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography
  publication-title: Gut
  doi: 10.1136/gutjnl-2011-300342
– volume: 2015
  year: 2015
  ident: hep32476-bib-0008-20241017
  article-title: Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk
  publication-title: Gastroenterol Res Pract
– volume: 74
  start-page: 474
  issue: 1
  year: 2021
  ident: hep32476-bib-0032-20241017
  article-title: Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement
  publication-title: Hepatology
  doi: 10.1002/hep.31726
– volume: 67
  start-page: 328
  issue: 1
  year: 2018
  ident: hep32476-bib-0006-20241017
  article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases
  publication-title: Hepatology
  doi: 10.1002/hep.29367
– volume: 67
  start-page: 1797
  issue: 5
  year: 2018
  ident: hep32476-bib-0010-20241017
  article-title: Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies
  publication-title: Hepatology
  doi: 10.1002/hep.29660
SSID ssj0009428
Score 2.5523453
Snippet Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of...
Background and AimsSeveral guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of...
Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of...
SourceID proquest
crossref
wiley
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1409
SubjectTerms Age
Aspartate aminotransferase
Cirrhosis
Diabetes
Diabetes mellitus (non-insulin dependent)
Fatty liver
Fibrosis
fibrosis scores
Hepatology
Liver cancer
Liver cirrhosis
Liver diseases
nonalcoholic steatohepatitis
Risk factors
type 2 diabetes mellitus
Title Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.32476
https://www.proquest.com/docview/2725989246
https://www.proquest.com/docview/2644020253
Volume 76
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA6lB_HiW6xWieLBy7bb7BtPIi1FUKRY6EFYkk2CpWUr7u6hPfkT_I3-EifZl4qCeFvIhGSTmeSbTOYLQueOBzjBYZEhqPDBQYnA5lxODcuWXkAjblKhEpxv79zh2L6ZOJMGuixzYXJ-iOrATVmGXq-VgVOWdGvS0CcBDjuxPUW3re5qKUA0qqmjAlu_qwpel6miy0HJKmSSblXz615UA8zPMFXvM4NN9Fj2ML9eMutkKetEq2_kjf_8hS20UeBPfJUrzDZqiHgHrd0WEfZdtBpNkxleSDxXFzbeX990sovgWDM9JZgtMaxAmMYcl8e2mGe5GuFpjAue1gSrA95aRMnHCvTrB3mnEZY0TZd5I7gIEu2h8aD_cD00ivcZjMhyfddQTPw9lykSOdMNGDMZ8TgljPkmkdKW3HQksyxHBuDE6Co9XzDfiYgHGiKItY-a0LQ4QBj0A1w_UwjGLJtTylzbFzB3FGRdn_da6KKcqTAqyMvVGxrzMKddJiGMZajHsoXOKtHnnLHjJ6F2Od1hYbRJSDzwBX1wSKH4tCoGc1MxFBqLRQYygB8BYRPHgi7puf29kXDYv9cfh38XPULrRCVY6GzHNmqmL5k4BtiTshOt3x-VfgAX
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NSsQwEB5WBfXiv_hvFA9e6nbTNm3Bi4iy6q6IuLAXKUmT4rJSxXYPevIRfEafxEna7qooiLdCJkyamUlmMsk3AHuej36CJ2JLcRVggBKjzTHJLcdN_JDH0uZKP3BuX7Jmxz3vet0aHFZvYQp8iOGBm7YMs15rA9cH0vURauidwoiduj4bgwld0dsEVNcj8KjQNZVVMe6ydX45rHCFbFofdv26G41czM-OqtlpTmfhthpjccGkfzDIxUH88g2-8b8_MQczpQtKjgqdmYeaShdgsl0m2Rfh5bqX9clDQu71nY331zfz3kVJYsCeMiKeCS5ChKeSVCe3RA4KTSK9lJRQrRnRZ7wjEk2far_f1OTtxSThef5cMCFlnmgJOqcnN8dNqyzRYMUOC5ilwfgbTGgcOZuFQtiC-pJTIQKbJombSNtLhON4SYhxjOnSCJQIvJj6qCSKOsswjqzVChBUEYz-bKWEcFzJuWBuoFB4HGlZIBursF-JKopL_HJdRuM-KpCXaYRzGZm5XIXdIeljAdrxE9FGJe-otNssoj6GgwHGpNi8M2xGi9NpFJ6qhwHSoAuJTjb1HBySEe7vTKLmyZX5WPs76TZMNW_arah1dnmxDtPIyS2uiW_AeP40UJvoBeViyyj7B4eABDQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSyQxEC58gHhZ3-j6iuLBS2sm3Z1Os6dFHcYnIgoehCbpJOygtLLTc9DT_oT9jf4SK-nuGRUF8daQCkmnqpKqVOorgK04QTshVnlgpBHooOSoc1zLIIxskspcU2lcgvPpGe9cRUfX8fUI_GpyYSp8iMGFm9MMv187BX_QdncIGvrHoMPOooSPwnjEqXAivX8xxI5KI19YFd0u6sLLaQMrRNnuoOvbw2hoYb62U_1B056Cm2aK1fuS251-qXbyp3fojd_8h2n4URug5HclMTMwYopZmDitQ-xz8HTR7d2Se0vu3IuN53__fbaL0cRDPfWIeiS4BRFZaNLc2xLdr-SIdAtSA7X2iLvhHZI4-sJZ_b4ibzcnVpblYzUIqaNE83DVPrjc6wR1gYYgD7nggYPib3HlUOQoT5WiiiVaMqUEZdZGVtPYqjCMbYpejO_SEkaJOGcJiohh4QKM4dBmEQgKCPp-1BilwkhLqXgkDPJOIi0XurUE2w2nsrxGL3dFNO6yCneZZbiWmV_LJdgckD5UkB0fEa007M5qre1lLEFnUKBHis0bg2bUNxdEkYW57yMNGpBoYrM4xCl53n4-SNY5OPcfP79Oug4T5_vt7OTw7HgZJplLtvCZjyswVv7tm1U0gUq15kX9BZr7Auo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+liver%E2%80%90related+events+by+age+and+diabetes+duration+in+patients+with+diabetes+and+nonalcoholic+fatty+liver+disease&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Zhang%2C+Xinrong&rft.au=Wong%2C+Grace+Lai%E2%80%90Hung&rft.au=Yip%2C+Terry+Cheuk%E2%80%90Fung&rft.au=Cheung%2C+Johnny+T.+K.&rft.date=2022-11-01&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=76&rft.issue=5&rft.spage=1409&rft.epage=1422&rft_id=info:doi/10.1002%2Fhep.32476&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_hep_32476
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon